Incredibly, a US FDA panel has left the door open for approval of Karyopharm’s selinexor in multiple myeloma, despite concerns about safety.
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
A value-based deal would boost prices should Astrazeneca's struggling heart-disease pill Brilinta outperform outcomes benchmarks.
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?